CHMP positive on J&J's new TB therapy Sirturo
This article was originally published in Scrip
Executive Summary
The EU's CHMP has given the go-ahead for conditional marketing for Janssen-Cilag's (Johnson & Johnson) novel treatment for tuberculosis, Sirturo (bedaquiline 100mg tablets), a year after it was approved in the US.